Vol 9, No 3 (2006)
- Year: 2006
- Articles: 10
- URL: https://osteo-endojournals.ru/osteo/issue/view/379
- DOI: https://doi.org/10.14341/osteo20063
Articles
Klinicheskie i biokhimicheskie aspekty issledovaniya insulinonodobnogo faktora rosta-1 v syvorotke krovi u retsipientov s narusheniyami kostnogo obmena posle peresadki serdtsa i pochki
Abstract
Insulin-like growth factor-1 (IGF-1), parathyroid hormone (PTH), biochemical markers of bone resorption and formation, bone mineral density (МПК) in spine and hip were determined in 46 recipients following heart transplantation (HI) and 79 -following kidney transplantation (KT) receiving triple immunosuppressive therapy. Serum IGF-1 in total recipients group (n=125) in mean was significantly lower then in health volunteers (187±102 and 250±51 ng/ml respectively; p<0,001). IGF-1 reduction was caused by glucocorticoids and cyclosporine hepatotoxicity and its level was associated with PTH level. Viral hepatitis and diabetes mellitus did not influence on IGF-1 level. There were significant inverse correlations between IGF-1 and МПК in recipients groups with normal PTH and without viral hepatitis and diabetes mellitus.
Osteoporosis and Bone Diseases. 2006;9(3):2-6
 |  |
Vliyanie somatotipa na mineral'nuyu plotnost' kostey skeleta, massu myshechnoy, soedinitel'noy i zhirovoy tkaney
Abstract
3300 healthy habitants of Ural region were examined with dichromatic bone densitometer «GE/Lunar» (USA). Then they were divided according to somatic type: 1100 normosthenic, 1100 hypersthenic and 1100 asthenic persons. There were formed age groups in female from 16, in male adolescents from 18 to 20 years old with 1-year pace, over 20 up to 80 years old with 5-years pace. It was evaluated how somatic type affects the mineral density of a skeleton, the mass of muscular, connective and adipose tissues. The mineral density in hypersthenic female adolescents was formed at the age of 16, in male - at the age of 18. In normosthenic and asthenic persons of the same age the mineral density was 95% and 92%. In hypersthenic women 80 years of age the mineral density was reduced by 30% from peak bone mass, in normosthenic - by 36% and in asthenic - by 41%. In men these values were 11,17 and 20% pro tanto.
Osteoporosis and Bone Diseases. 2006;9(3):7-10
| |
Rasprostranennost' osteopenicheskogo sindroma i osobennosti kostnogo metabolizma u zdorovykh detey primorskogo kraya
Abstract
We investigated 130 healthy children and adolescences, its dates of dual-energy X-ray absorbtiometry, bone metabolism markers. The formation of bone mass peak, bone's mineralization in healthy children is depending on age, anthropometric status, sex, dietary with uneven activity in the different local of skeleton. The level of bone metabolism markers is depending on period of life, with maximal dates in patient's 12-14 yeas old. The level of osteopenic syndrome in healthy children consist 15,39%.
Osteoporosis and Bone Diseases. 2006;9(3):11-13
| |
Vliyanie narusheniya kostnogo metabolizma na sostoyanie tkaney parodonta u muzhchin reproduktivnogo vozrasta s sakharnym diabetom 1 tina i puti korrektsii
Abstract
The aims of this study were to investigate the influence of alterations in bone metabolism and in hormonal and biochemical parameters on periodontium tissue as well as to estimate the optimal algorithm of investigation and treatment in men with diabetes mellitus type 1.
During the first stage (12 months) the comparative analysis of conditions of pariodontium tissue was conducted in 60 men of childbearing age with diabetes mellitus type 1 and in 25 men of the control group. During the second stage (12 months) the markers of bone metabolism and the conditions of paradontium tissue were studied in 26 men of childbearing age with diabetes mellitus type 1 and in 25 men of the control group.
The marker of bone resorption (CTX) was significantly lower (372,7 pkg/ml versus 473,0 pkg/ml; p= 0,006) and the marker of bone formation (OK) was significantly higher (27,6 ng/ml compared to 21,42 ng/ml; p< 0,005) in the group of patients who received ALPHA D3-TEVA (alfacalcidol 0,75mkg/day) and 2 tab CALCEMIN ADVANCE (calcium 1000 mg, cholecalciferol 400 UI) in comparison with the control group.
Conclusion: the treatment with Calcium and Vitamin D is effective for prevention of bone resorbtion, particularly in jaws.
Osteoporosis and Bone Diseases. 2006;9(3):14-22
| |
Ibandronat (Bonviva) - novye vozmozhnosti v lechenii osteonoroza: povyshenie priverzhennosti k terapii - optimizatsiya iskhodov lecheniya
Abstract
Osteoporosis and Bone Diseases. 2006;9(3):23-30
| |
Vliyanie strontsiya ranelata na chastotu perelomov tel pozvonkov pri osteoporoze v zavisimosti ot faktorov riska
Abstract
Osteoporosis and Bone Diseases. 2006;9(3):31-35
| |
Vozrastnoy gipogonadizm i osteoporoz: patofiziologiya i vozmozhnosti lecheniya
Abstract
Osteoporosis and Bone Diseases. 2006;9(3):36-41
| |
Kal'tsiy i vitamin D: razocharovanie ili utochnenie pokazaniy?
Abstract
Osteoporosis and Bone Diseases. 2006;9(3):42-43
| |
Metod farmakologicheskoy korrektsii metabolizma kostnoy tkani dlya uluchsheniya rezul'tatov endoprotezirovaniya tazobedrennogo sustava
Abstract
Пособие для врачей посвящено улучшению результатов эндопротезирования пациентов, страдающих остеопорозом или другими заболеваниями, при которых нарушается ремоделирование костной ткани (болезнь Педжета, гиперпаратиреоидная остеодистрофия после удаления аденомы околощитовидной железы, остеомаляция). Разработанный способ фармакологической коррекции нарушений ремоделирования костной ткани защищен патентом (патент РФ на изобретение № 2176519 от 10.12.01) и основан на комбинированной лекарственной терапии с использованием кальцитонина (миакальцика применяемого интраназально или в виде внутримышечных инъекций), альфакальцидола (альфа-D3 ТЕВА, Этальфа оксидевита) и препаратов кальция.
Приведены факторы риска асептической нестабильности эндопротезов и схемы профилактики и лечения в зависимости от степени риска ее развития. Метод предназначен для улучшения результатов эндопротезирования и реэндопротезирования тазобедренного сустава.
Osteoporosis and Bone Diseases. 2006;9(3):44-47
| |
| |